Serum Metabolites Differentiate Amnestic Mild Cognitive Impairment From Healthy Controls and Predict Early Alzheimer's Disease via Untargeted Lipidomics Analysis
Open Access
- 2 August 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12, 704582
Abstract
Background and Aim:Alzheimer's disease (AD) is the most common type of dementia and presents with metabolic perturbations early in the disease process. In order to explore biomarkers useful in predicting early AD, we compared serum metabolites among patients suffering different stages of AD.Methods:We recruited 107 participants including 23 healthy controls (HC), 21 amnestic mild cognitive impairment (aMCI), 24 non-amnestic mild cognitive impairment (naMCI) and 39 AD patients. Via liquid chromatography-mass spectrometry based serum untargeted lipidomics analysis, we compared differences in serum lipid metabolites among these patient groups and further elucidated biomarkers that differentiate aMCI from HC.Results:There were significant differences of serum lipid metabolites among the groups, and 20 metabolites were obtained under negative ion mode from HC and aMCI comparison. Notably, 16:3 cholesteryl ester, ganglioside GM3 (d18:1/9z-18:1) and neuromedin B were associated with cognition and increased the predictive effect of aMCI to 0.98 as revealed by random forest classifier. The prediction model composed of MoCA score, 16:3 cholesteryl ester and ganglioside GM3 (d18:1/9z-18:1) had good predictive performance for aMCI. Glycerophospholipid metabolism was a pathway common among HC/aMCI and aMCI/AD groups.Conclusion:This study provides preliminary evidence highlighting that 16:3 cholesteryl ester were useful for AD disease monitoring while ganglioside GM3 (d18:1/9z-18:1) and neuromedin B discriminated aMCI from HC, which can probably be applied in clinic for early predicting of AD.Keywords
This publication has 50 references indexed in Scilit:
- Pathological significance of ganglioside clusters in Alzheimer’s diseaseJournal of Neurochemistry, 2011
- ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with ADProceedings of the National Academy of Sciences, 2010
- A Comparison Study of Mild Cognitive Impairment With 3 Memory Tests Among Chinese IndividualsAlzheimer Disease & Associated Disorders, 2009
- Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: Direct interaction of GM3 with VEGFR-2Glycobiology, 2008
- The involvement of lipid rafts in Alzheimer's disease (Review)Molecular Membrane Biology, 2006
- Enhanced GM1 ganglioside catabolism in cultured fibroblasts from Alzheimer patientsNeurobiology of Aging, 2005
- Selective Cell-Cycle Arrest and Induction of Apoptosis in Proliferating Neural Cells by Ganglioside GM3Experimental Neurology, 2001
- Structural Transitions Associated with the Interaction of Alzheimer β-Amyloid Peptides with GangliosidesJournal of Biological Chemistry, 1998
- Regulation and Immunolocalization of Acyl-Coenzyme A:Cholesterol Acyltransferase in Mammalian Cells as Studied with Specific AntibodiesJournal of Biological Chemistry, 1995
- Gangliosides in the human brain development and agingNeurochemistry International, 1992